
LQDA Stock Forecast & Price Target
LQDA Analyst Ratings
Bulls say
Liquidia is a promising company with a diverse pipeline and a potential blockbuster drug in Yutrepia. While the Supreme Court ruling brings positive news, there are also ongoing legal challenges that could impact the company's success and revenue growth. Overall, with its strong financial standing and potential for growth, Liquidia could be a good stock to consider for long-term investment.
Bears say
Liquidia is facing potential legal challenges and competition in the PH market as it works towards FDA approval for YUTREPIA, its main product for treating PH. The company is also investing heavily in R&D for L606, an investigational drug with uncertain outcomes. Additionally, the company's financials could be impacted by a potential injunction due to a patent infringement lawsuit. With uncertainty surrounding key factors such as legal decisions and future revenue potential, the outlook for Liquidia's stock is negative.
This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
LQDA Analyst Forecast & Price Prediction
Start investing in LQDA
Order type
Buy in
Order amount
Est. shares
0 shares